Januvia 50mg
Generic: Sitagliptinby MSD Pharmaceuticals Pvt. Ltd.

Similar medicines
View allAbout Januvia 50mg
Januvia 50mg is MSD's sitagliptin tablet for type 2 diabetes at the strength the labels reserve for one group: adults whose kidney function has fallen to an eGFR of 30 to below 45. Each film-coated tablet holds sitagliptin phosphate equivalent to 50 mg of sitagliptin, a DPP-4 inhibitor taken once a day. We sell the Indian pack from MSD Pharmaceuticals Pvt Ltd; the carton in our product photo reads "Sitagliptin Phosphate Tablets IP", "Januvia 50 mg" and "1 strip of 7 film-coated tablets". Our packs hold 28, 56 and 84 tablets (4, 8 and 12 strips), which last 28, 56 and 84 days at one tablet a day, from $1.88 a tablet before shipping (as of November 2026; the pack selector shows the current price).
Three points first. One: for most adults the label dose is 100 mg once daily, not 50 mg. Both the US and UK Januvia labels give 50 mg only at an eGFR (or GFR) of 30 to below 45, so this strength belongs with a kidney test result and a doctor's decision, and the right dose can change as kidney function changes. Two: the labels ask for a kidney function test before starting and at intervals afterwards. Three: in the US, FDA-approved generic sitagliptin 50 mg tablets from Teva, Sandoz and Apotex have been listed for sale since January to May 2026, and pharmacies pay about $3.72 a tablet for them against about $10.55 for Januvia (NADAC, effective 21 October 2026). This page uses the current US Januvia prescribing information, the UK Januvia SmPC and Indian pharmacy listings; the full list is at the end.
Januvia 50mg at a glance
| Active ingredient | Sitagliptin 50 mg, as sitagliptin phosphate, in one film-coated tablet (carton in our product photo; Truemeds, PharmEasy and Medkart listings) |
| Brand and maker | Januvia, MSD Pharmaceuticals Pvt Ltd (India), per the Truemeds and Medkart listings and the MSD logo on the carton in our product photo. PharmEasy names Abbott Healthcare Pvt Ltd under "Made by", so read the maker line on the strip you receive |
| Drug class | DPP-4 inhibitor (dipeptidyl peptidase 4 inhibitor) |
| Regulatory status | Januvia 50 mg is licensed in the US (FDA), the UK (MHRA), Canada and Australia, and generic sitagliptin is sold in all four. This Indian pack is not registered with the FDA, MHRA, TGA or Health Canada |
| Usual dose from the label | US and UK labels: 100 mg once daily for most adults; 50 mg once daily at an eGFR of 30 to below 45; 25 mg once daily below 30 or on dialysis. With or without food |
| Half-life | Apparent terminal half-life 12.4 hours after a single 100 mg dose in healthy volunteers; peak blood levels 1 to 4 hours after a dose (US label 12.3) |
| Packs | 28, 56 and 84 tablets (strips of 7); 28, 56 and 84 days at one tablet a day |
| Price per tablet | $1.88 to $2.32 before shipping; $1.88 to $3.21 with shipping (our arithmetic) |
| Delivery | 7 to 14 business days to the US, UK, Australia and Canada; $25 shipping under $149, free from $149 |
Price per tablet
Prices are as of November 2026; the pack selector shows the current price. One tablet is one day's dose at the label's 50 mg once daily, so the price per tablet is also the price per day. The per-tablet figures are our arithmetic.
| Pack | Price | Per tablet | Shipping | Per tablet with shipping |
|---|---|---|---|---|
| 28 tablets (4 strips, 28 days) | $65 | $2.32 | $25 | $3.21 |
| 56 tablets (8 strips, 56 days) | $110 | $1.96 | $25 | $2.41 |
| 84 tablets (12 strips, 84 days) | $158 | $1.88 | Free | $1.88 |
The 84 pack is the cheapest per tablet before shipping as well as after it, and it is the only single pack above the $149 free shipping line. A 28 pack plus a 56 pack ($175, 84 tablets) also ships free, but works out at about $2.08 a tablet, more than the single 84 pack (our arithmetic).
Buy for the dose you are on now. This strength matches one band of kidney function. If your eGFR rises to 45 or above, the label dose becomes 100 mg; if it falls below 30, the label dose becomes 25 mg. Your doctor may change your dose after a kidney test, so a large pack makes sense only if your kidney function has been stable. Delivery takes 7 to 14 business days, so order before your current supply runs out, and do not stretch or skip tablets while you wait.
If your doctor prescribes 100 mg. Two of these tablets a day would cost $3.76 to $4.64 a day with our packs before shipping, against $2.14 to $2.63 a tablet for our Januvia 100mg packs before shipping (our arithmetic, November 2026 prices). Take the strength your doctor prescribes, as whole tablets.
Compared with US Januvia and US generics
| Januvia 50mg (ours, India) | Januvia 50 mg (US) | US generic sitagliptin phosphate 50 mg | Zituvio 50 mg (US) | |
|---|---|---|---|---|
| Maker | MSD (India) | Merck Sharp & Dohme | Teva, Sandoz or Apotex | Zydus Lifesciences |
| FDA approved | Not registered with the FDA | Yes (NDA 021995, 2006) | Yes, rated AB (therapeutically equivalent) to Januvia | Yes (NDA 211566, 2023), sitagliptin free base under its own application, not a generic of Januvia |
| Cost per tablet | $1.88 to $2.32 before shipping; $1.88 to $3.21 with shipping | NADAC $10.54591 | NADAC $3.71652 | NADAC $10.05821 |
| Cost of 28 tablets | $65 ($90 with shipping) | About $295.29 | About $104.06 | About $281.63 |
| US cash price example | n/a | n/a | Cost Plus Drugs: 30 for $46.14 with fee and shipping, about $1.54 a tablet | Cost Plus Drugs, Zydus unbranded sitagliptin: $1.37962 a tablet plus fee and shipping |
NADAC is the average price US retail pharmacies pay to buy a medicine, published weekly by the US Medicaid programme (CMS). It is not the price a patient pays at the counter, which adds a dispensing fee and the pharmacy's margin, and insurance can change what you pay a great deal. All four NADAC figures are per-tablet rows in the file dated 4 November 2026, each effective 21 October 2026: Januvia 50 mg (Merck NDCs 0006-0112), generic sitagliptin phosphate 50 mg (Teva 0480-2608, Sandoz 0781-5768 and Apotex 60505-3644 NDCs) and Zituvio 50 mg (Zydus NDC 70710-1241). The first NADAC row for generic sitagliptin phosphate 50 mg was effective 5 August 2026, at $3.68380. The 28-tablet figures are our arithmetic.
Are US generics cheaper than ours? Often, yes, for US cash buyers. US pharmacies pay about $3.72 a tablet for generic sitagliptin 50 mg (NADAC, effective 21 October 2026), more than our $1.88 to $2.32, but low-cost US pharmacies now sell it for less than we do: Mark Cuban Cost Plus Drugs lists generic sitagliptin phosphate 50 mg at $35.89 for 30 tablets plus a $5 dispensing fee and $5.25 shipping, $46.14 or about $1.54 a tablet in all, and $107.67 for 90 plus the $5 fee, about $1.31 a tablet if shipping is the same (Cost Plus Drugs price list, checked 10 November 2026; our arithmetic). An insurance copay can be lower still. If you are in the US with a prescription, compare these prices and your copay before ordering from overseas. A US pharmacy can also check your other medicines and keep a record of your kidney-based dose, which an overseas order cannot.
The FDA approved generic sitagliptin phosphate tablets (25, 50 and 100 mg) from Watson/Teva (ANDA 202327, 29 December 2025), Sandoz (ANDA 202387, 14 January 2026) and Apotex (ANDA 202425, 20 January 2026). The FDA's NDC directory lists marketing start dates of 14 January 2026 for Sandoz and 28 May 2026 for the Teva and Apotex 50 mg tablets. Zydus also sells an unbranded sitagliptin under its Zituvio application (NDC 70710-1900, listed as an authorized generic). We have seen no bioequivalence study comparing the Indian Januvia pack with US Januvia, and any switch between products is a decision for your doctor, with closer glucose checks afterwards.
Which strength to choose
The strength depends on kidney function, not on how high your blood sugar is. The US label gives the bands as eGFR in mL/min/1.73 m2 and the UK label as GFR in mL/min; the cut-offs are the same.
| Kidney function | Label dose (US and UK) | Our product |
|---|---|---|
| eGFR 45 or above | 100 mg once daily (no adjustment) | Januvia 100mg |
| eGFR 30 to below 45 (moderate renal impairment) | 50 mg once daily | Januvia 50mg (this page) |
| eGFR below 30, or end-stage kidney disease on haemodialysis or peritoneal dialysis | 25 mg once daily, without regard to the timing of dialysis | Januvia 25mg |
Sources: US Januvia label 2.2; UK Januvia SmPC 4.2. The label dose is the same for all strengths: one tablet once a day. Neither label gives a 50 mg dose for people with an eGFR of 45 or above, so this strength is below the label dose for them. The 50 mg tablet is not a "milder" or "starter" version of Januvia: the labels have no step-up from 50 mg to 100 mg, only kidney bands.
Why the dose is lower. Sitagliptin leaves the body mainly through the kidneys. At an eGFR of 30 to below 45, blood levels (AUC) of sitagliptin were about twice those in people with normal kidneys, and about four times as high below 30, including people on haemodialysis (US label 12.3; UK SmPC 5.2). The UK label says the lower doses aim "to achieve plasma concentrations of sitagliptin similar to those in patients with normal renal function". At an eGFR of 45 to below 60, exposure rose about 1.6-fold, which the UK label says is not clinically relevant, so no change is needed there.
Combination tablets at this kidney level. The US Janumet label says Janumet (sitagliptin with metformin) is "not recommended" at an eGFR of 30 to below 45, because people at that level need a lower sitagliptin dose than the fixed combination gives. Our Janumet 50mg/500mg and Janumet 50mg/1000mg pages explain this. If your doctor wants you on both medicines at this kidney level, separate tablets such as this one may be used; that is your doctor's decision.
How to take Januvia 50mg
- Take one tablet once a day, exactly as your doctor prescribes, with or without food (US label 2.1; UK SmPC 4.2).
- If you miss a dose, the US Medication Guide says to take it as soon as you remember; if you do not remember until your next dose is due, skip the missed dose and go back to your usual schedule. "Do not take two doses of JANUVIA at the same time." The UK label says a double dose should not be taken on the same day.
- Have your kidney function checked before you start and at intervals afterwards (US label 2.2 and 5.3; UK SmPC 4.2). The US label says older people need kidney checks more often (8.5). Ask your doctor whether your dose should change after each result.
- Tell your doctor right away if you have a fever, an injury, an infection or surgery, because the amount of diabetes medicine you need may change (US Medication Guide).
- Check your blood sugar as your doctor tells you, and keep to your diet and exercise plan. Your doctor will check your HbA1c with blood tests.
- If you also take a sulfonylurea (such as glimepiride or gliclazide) or insulin, ask your doctor whether that dose should be lowered.
- Never start, stop, switch or combine diabetes medicines on your own.
The US and UK labels describe Januvia 50 mg as a light beige, round, film-coated tablet with "112" on one side. The Indian tablet may look different, so judge your supply by the carton and strip, not by the US or UK description.
How well it works
The trials behind the labels mostly used 100 mg in people with normal kidney function. In two placebo-controlled monotherapy trials (18 and 24 weeks), Januvia 100 mg lowered HbA1c by 0.6 and 0.8 percentage points more than placebo, from a mean baseline of about 8.0% (US label 14.1, Table 6). In the 24-week trial, 41% reached an HbA1c below 7%, against 17% on placebo.
For this strength, the US label describes a placebo-controlled study in 91 people with type 2 diabetes and reduced kidney function (creatinine clearance below 50 mL/min). People with moderate kidney impairment took 50 mg a day and those with severe impairment or on dialysis took 25 mg. The label says safety and tolerability "were generally similar to placebo", and the falls in HbA1c and fasting glucose against placebo were "generally similar to those observed in other monotherapy studies" (14.1). Over 12 weeks, serum creatinine rose by a mean 0.12 mg/dL in the 37 people with moderate impairment on 50 mg, against 0.07 mg/dL in the 14 on placebo; the label says the clinical significance of this difference is not known (6.1).
In the TECOS trial, described in the UK label, people with an eGFR of 30 to below 50 at the start took 50 mg a day; across the whole trial, HbA1c was on average 0.29 percentage points lower with sitagliptin than with placebo on top of usual care (UK SmPC 5.1). Note that TECOS used a cut-off of 50 for the lower dose, while the current labels use 45.
Sitagliptin works with your body's own incretin hormones: it raises insulin release and lowers glucagon when blood sugar is normal or high (UK SmPC 5.1). On its own, or with metformin, it caused low blood sugar at about the same rate as placebo in the trials.
Lower doses and extra care for some groups
- Kidney impairment. See the strength table above. The US label adds that there have been postmarketing reports of worsening kidney function, including acute kidney failure sometimes needing dialysis, and that some of these involved people with kidney impairment "some of whom were prescribed inappropriate doses of sitagliptin" (5.3). Taking 100 mg when your eGFR calls for 50 mg is one way that happens.
- Older people. The UK label says no dose adjustment is needed based on age (4.2). The US label says kidney function should be checked more often in older people, because sitagliptin is substantially excreted by the kidney and kidney function falls with age (8.5).
- Liver problems. No dose change is needed for mild to moderate liver impairment. The UK label says Januvia has not been studied in severe liver impairment "and care should be exercised" (4.2).
- Severe kidney impairment and strong CYP3A4 inhibitors. The UK label says strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) could change sitagliptin levels in people with severe kidney impairment or end-stage kidney disease, and that this has not been studied (4.5).
- People on a sulfonylurea or insulin. A lower dose of the sulfonylurea or insulin "may be required" (US label 5.4) or "may be considered" (UK SmPC 4.2) to reduce the risk of low blood sugar.
- Children. The US label says safety and effectiveness have not been established in children (8.4). The UK label says sitagliptin "should not be used in children and adolescents 10 to 17 years of age because of insufficient efficacy" (4.2).
Pancreatitis
The US label reports postmarketing cases of acute pancreatitis, "including fatal and non-fatal hemorrhagic or necrotizing pancreatitis", and says to stop Januvia promptly if pancreatitis is suspected (5.1). It is unknown whether people with a history of pancreatitis are at higher risk, and Januvia has not been studied in them (US label 1). In a pooled analysis of 19 trials (10,246 patients), acute pancreatitis occurred at 0.1 per 100 patient-years in both the sitagliptin and control groups (US 6.1). In TECOS, adjudication-confirmed pancreatitis occurred in 0.3% on sitagliptin and 0.2% on placebo (UK SmPC 4.8).
Before you start, the US Medication Guide says to tell your doctor if you have ever had pancreatitis, gallstones, kidney problems, high blood triglycerides or a history of alcoholism. The UK label says that if acute pancreatitis is confirmed, Januvia "should not be restarted", and that caution should be used in people with a history of pancreatitis (4.4).
Heart failure
The US label says an association between DPP-4 inhibitor treatment and heart failure "has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class" (5.2). It tells doctors to weigh the risks and benefits before starting Januvia in people at risk of heart failure, "such as those with a prior history of heart failure and a history of renal impairment". That second group includes most people who are prescribed this strength, so tell your doctor about any heart problems before you start.
For sitagliptin itself, the UK label reports TECOS: 14,671 people with type 2 diabetes and established cardiovascular disease, 3,324 of them with an eGFR below 60, took sitagliptin or placebo on top of usual care for a median of 3 years. People with an eGFR below 30 were not enrolled.
| TECOS outcome | Sitagliptin (7,332) | Placebo (7,339) | Hazard ratio (95% CI) |
|---|---|---|---|
| Cardiovascular death, non-fatal heart attack, non-fatal stroke or hospital stay for unstable angina | 839 (11.4%) | 851 (11.6%) | 0.98 (0.89 to 1.08) |
| Hospital admission for heart failure | 228 (3.1%) | 229 (3.1%) | 1.00 (0.83 to 1.20) |
| Cardiovascular death | 380 (5.2%) | 366 (5.0%) | 1.03 (0.89 to 1.19) |
| Death from any cause | 547 (7.5%) | 537 (7.3%) | 1.01 (0.90 to 1.14) |
Selected rows. Source: UK Januvia SmPC 5.1, Table 3 (intention-to-treat population). The label says sitagliptin "did not increase the risk of major adverse cardiovascular events or the risk of hospitalisation for heart failure" compared with usual care without it.
Signs of heart failure (US Medication Guide): increasing shortness of breath or trouble breathing, especially when you lie down; swelling or fluid retention, especially in the feet, ankles or legs; an unusually fast increase in weight; and unusual tiredness. Contact your doctor right away if you notice them.
Low blood sugar (hypoglycaemia)
Alone or with metformin or pioglitazone, sitagliptin rarely causes low blood sugar: in pooled trials of those uses, 1.2% on Januvia 100 mg reported it against 0.9% on placebo (US label 6.1). The risk rises when it is added to a sulfonylurea or insulin:
| 24 week add-on trial | Januvia 100 mg | Placebo |
|---|---|---|
| Added to glimepiride (with or without metformin) | 12.2% | 1.8% |
| Added to insulin (with or without metformin) | 15.5% | 7.8% |
Source: US Januvia label 6.1, Table 3 (patients with at least one report of symptomatic low blood sugar). Severe episodes were 0% in both glimepiride groups and 0.6% against 0.3% in the insulin trial. The UK label gives 4.7% to 13.8% with a sulphonylurea and 9.6% with insulin (4.8). These trials used 100 mg; the labels give no separate figures for 50 mg.
Signs (US Medication Guide): headache, drowsiness, irritability, hunger, dizziness, confusion, sweating, feeling jittery, weakness and a fast heartbeat. Ask your doctor how to treat a low reading. If someone is unconscious or cannot swallow, call emergency services; as general first aid, do not put food or drink in their mouth.
Side effects
In the US label's trials, overall adverse reactions with Januvia were similar to placebo when it was used alone or with metformin or pioglitazone (6.1). The most common were:
| Effect | Januvia 100 mg | Placebo | Trials |
|---|---|---|---|
| Nasopharyngitis (stuffy or runny nose, sore throat) | 5.2% | 3.3% | Monotherapy, 18 or 24 weeks (Table 1) |
| Diarrhoea | 3.0% | 2.3% | Pooled monotherapy, add-on to metformin and add-on to pioglitazone |
| Abdominal pain | 2.3% | 2.1% | Same pooled trials |
| Nausea | 1.4% | 0.6% | Same pooled trials |
Selected rows. Source: US Januvia label 6.1. Headache was 5.1% against 3.9% when added to pioglitazone and 5.9% against 2.3% when added to glimepiride. The UK label lists headache and hypoglycaemia as common, dizziness, constipation and itching as uncommon, and low platelets (thrombocytopenia) as rare (4.8).
Other warnings and postmarketing reports. Serious allergic reactions (anaphylaxis, angioedema and skin reactions including Stevens-Johnson syndrome) began within the first 3 months of treatment, some after the first dose (US 5.5). Severe and disabling joint pain can start from one day to years after starting a DPP-4 inhibitor (US 5.6). Postmarketing cases of bullous pemphigoid, a blistering skin condition, needing hospital treatment have been reported with DPP-4 inhibitor use (US 5.7). Postmarketing reports, without a reliable frequency, also include liver enzyme rises, tubulointerstitial nephritis, constipation, vomiting, headache, muscle, limb and back pain, itching, mouth ulcers, stomatitis and rhabdomyolysis (US 6.2). The US list also includes rash, urticaria and cutaneous vasculitis (6.2). The UK label adds interstitial lung disease, frequency not known (4.8).
When to get urgent help
Get emergency help, or ask someone to call for you, if you have:
- Swelling of the face, lips, tongue or throat, trouble breathing or swallowing, hives or a rash. The US Medication Guide says to stop taking Januvia and call your doctor right away or get emergency medical help.
- Pain in your stomach area that is severe and will not go away, which may go through to your back, with or without vomiting: possible pancreatitis. Stop the tablets and call your doctor right away (US Medication Guide).
- Low blood sugar that does not improve after taking sugar, comes back, or causes confusion, fits, fainting or loss of consciousness.
- Sudden or worsening breathlessness, especially when lying down, or fast swelling of the legs or weight gain: possible heart failure.
- Taking more than your prescribed dose, or a child swallowing the tablets. The US Medication Guide says to call your doctor or local Poison Control Center right away. Poison lines (our addition, not from the label): US 1-800-222-1222, Australia 13 11 26. The UK label says healthy volunteers were given single doses up to 800 mg in trials (4.9); that is not a safe dose for you to take.
Tell the emergency staff that you take sitagliptin (Januvia 50mg), how much and when, and what your last kidney test showed if you know it.
Also get prompt medical advice for blisters or skin erosions (US 5.7), severe joint pain (US 5.6), much less urine than usual or new swelling (possible kidney problems; our advice), and, in our view, unusual bruising or bleeding (the UK label lists low platelets as a rare effect).
Who should not take Januvia 50mg
Never take it if you have had a serious allergic reaction to sitagliptin, such as anaphylaxis or angioedema (US label 4). The UK label's contraindication covers allergy to sitagliptin or to any of the tablet's ingredients (4.3). These are the only contraindications in either label.
Should not use, or use only with care:
- Type 1 diabetes: the US label says Januvia "should not be used in patients with type 1 diabetes" (1); the UK label says it should not be used in type 1 diabetes "or for the treatment of diabetic ketoacidosis" (4.4).
- Kidney function that does not match this strength: an eGFR of 45 or above (label dose 100 mg) or below 30 (label dose 25 mg). This strength is not suitable for either group.
- Pregnancy: the UK label says Januvia "should not be used during pregnancy" because of a lack of human data (4.6). The US label says the limited data are not enough to inform a drug-associated risk, and that poorly controlled diabetes in pregnancy carries risks for mother and baby (8.1).
- Breastfeeding: the UK label says Januvia "should not be used during breast-feeding" (4.6). The US label says the benefits of breastfeeding should be weighed with the mother's need for Januvia and any possible effects on the baby (8.2).
- Children and teenagers: see the groups section above.
- A history of pancreatitis: not studied (US); use with caution (UK).
- A history of angioedema with another DPP-4 inhibitor: the US label says "use caution" (5.5).
- People at risk of heart failure, including people with kidney impairment: weigh the risks and benefits first (US 5.2).
- Severe liver impairment: not studied; "care should be exercised" (UK 4.2).
Medicines that interact
- Sulfonylureas and insulin: more low blood sugar; a lower dose of these may be needed (US 5.4, 7.1; UK 4.4).
- Digoxin: sitagliptin raised digoxin exposure (AUC) by about 11% and peak levels by about 18%; no digoxin dose change is recommended, but people at risk of digoxin toxicity should be monitored (UK 4.5).
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin): could alter sitagliptin levels in severe kidney impairment or end-stage kidney disease; not studied (UK 4.5).
- Ciclosporin: a single 600 mg dose raised sitagliptin AUC by about 29% and peak levels by about 68%, which the UK label says is not clinically meaningful (4.5).
- Metformin, glyburide, simvastatin, rosiglitazone, warfarin and oral contraceptives: sitagliptin did not meaningfully change their levels in clinical studies (UK 4.5).
Tell your doctor or pharmacist about every medicine and supplement you take before you start, and before you start anything new. People with reduced kidney function often take several medicines whose doses also depend on the kidneys.
Prescription and legal status
In India, Truemeds and Medkart mark Januvia 50 mg as prescription required, and the carton in our product photo carries "Rx". In the US, Januvia (NDA 021995, approved 16 October 2006), Zituvio and generic sitagliptin are prescription medicines, and the FDA says personal importation of unapproved medicines is illegal in most circumstances. In the UK, Januvia 50 mg (PLGB 53095/0039) is a prescription only medicine (emc), and the NHS dm+d lists generic sitagliptin 50 mg tablets from several makers as POM. In Canada, Januvia 50 mg (DIN 02388847) is a marketed prescription medicine, and the Health Canada Drug Product Database lists many marketed generic sitagliptin 50 mg tablets, among them Apo-Sitagliptin, Sandoz Sitagliptin and PMS-Sitagliptin. In Australia, sitagliptin 50 mg is on the PBS (item 9181F, 28 tablets, Authority Required (STREAMLINED)) as Januvia and six other brands (Sitagliptin Lupin, Sitagliptin Mylan, Sitagliptin SUN, Sitagliptin Sandoz Pharma, Sitaglo and Xelevia); the dispensed price for the maximum quantity is A$31.55 and a general patient pays A$25.00 (PBS schedule, checked 10 November 2026). This Indian Januvia pack is not registered with the FDA, the MHRA, the TGA or Health Canada. Check the rules where you live.
Buying genuine Januvia 50mg
The MHRA warns that "Any medicine not authorised for sale in the UK can be unsafe or ineffective and there is no way of knowing what is in them or the negative health effects they can have", and advises UK buyers to "Only use UK-registered pharmacies, including online pharmacies displaying the official green cross logo". That warning covers this Indian pack, which is not authorised in the UK. When your order arrives, read the carton and strip: they should say Januvia 50 mg and sitagliptin phosphate, name the maker, and carry a batch number and an expiry date. These checks cannot prove that tablets are genuine, because counterfeiters copy packaging. Check your blood sugar closely during the first weeks on any new supply, and tell your doctor if your readings change. If a batch causes unusual symptoms, seek medical advice and report it to your medicines regulator (the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US, the TGA in Australia or Health Canada) as well as to us.
Delivery
We ship Januvia 50mg to the US, UK, Australia and Canada in plain packaging with tracking. Standard delivery takes 7 to 14 business days to most countries. Shipping costs a flat $25 on orders under $149 and is free from $149. Storage advice differs: PharmEasy says below 25°C in a cool and dry place, Medkart says room temperature, and the Truemeds listing gives both "below 30°C" and "below 25°C"; the UK label says store below 25°C and the US label 20°C to 25°C. Keep the tablets in the strip until you take them, and follow the carton you receive. Diabetes tablets should not run out: order before your current supply ends, and do not ration your tablets while you wait. See our shipping page and refund policy.
Related guides
- Januvia vs Tradjenta: sitagliptin and linagliptin compared, including kidney dosing and 2026 prices
- Generic Janumet (sitagliptin and metformin): now in US pharmacies, strengths, doses and cost
- Onglyza (saxagliptin): US brand discontinued, generic dosing, heart failure warning and cost
Other DPP-4 inhibitors handle kidney function differently. The US Tradjenta label says no dose adjustment is recommended for kidney impairment (8.6), so Trajenta 5mg (linagliptin) is one tablet at every eGFR. The US saxagliptin label gives 2.5 mg once daily at an eGFR below 45 (2.2), the strength of Onglyza 2.5mg. Any change of medicine is your doctor's decision.
Sources
- JANUVIA (sitagliptin) tablets, US prescribing information and Medication Guide, Merck Sharp & Dohme LLC (DailyMed setid f85a48d0-0407-4c50-b0fa-7673a160bf01, SPL version 71, effective 14 November 2024, still current on 10 November 2026): sections 1, 2.1, 2.2, 3, 4, 5.1 to 5.7, 6.1, 6.2, 7.1, 8.1, 8.2, 8.4 to 8.6, 10, 12.3, 14.1, 16, 17. DailyMed
- Januvia 25 mg, 50 mg and 100 mg film-coated tablets, UK SmPC, Merck Sharp & Dohme (UK) Limited (PLGB 53095/0039 for 50 mg, POM), date of revision 12 October 2023: sections 3, 4.1 to 4.9, 5.1, 5.2, 6.4, 6.5. emc
- JANUMET US prescribing information, Merck Sharp & Dohme LLC (DailyMed setid d19c7ed0-ad5c-426e-b2df-722508f97d67, SPL version 61): renal "not recommended" statement. DailyMed
- TRADJENTA US prescribing information (DailyMed setid c797ea5c-cab7-494b-9044-27eba0cfe40f, SPL version 32): section 8.6. Saxagliptin tablets US prescribing information, Glenmark (DailyMed setid e286ffd4-c598-47fb-af06-2e15f7e6f99f): section 2.2.
- US Food and Drug Administration, openFDA Drugs@FDA and NDC directory: NDA 021995 (Januvia), NDA 211566 (Zituvio), ANDA 202327, 202387 and 202425 (generic sitagliptin phosphate, AB rated); searched 10 November 2026.
- Cost Plus Drugs (Mark Cuban Cost Plus Drug Company) price list API: generic sitagliptin phosphate 50 mg $1.19638 a tablet, 30 count $35.89, $5 dispensing fee, $46.14 with shipping; Zydus sitagliptin 50 mg $1.37962 a tablet; read 10 November 2026. Cost Plus Drugs
- Green JB et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes (TECOS). N Engl J Med 2015. PMID 26052984. Rosenstock J et al. CARMELINA, JAMA 2019, PMID 30418475; CAROLINA, JAMA 2019, PMID 31536101. Scirica BM et al. SAVOR-TIMI 53, N Engl J Med 2013, PMID 23992601 (Figure 1).
- Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC) 2026: Januvia 50 mg $10.54591, sitagliptin phosphate 50 mg $3.71652, Zituvio 50 mg $10.05821 per tablet, file as of 4 November 2026, effective 21 October 2026. data.medicaid.gov
- Pharmaceutical Benefits Scheme, item 9181F, sitagliptin 50 mg tablet, 28; checked 10 November 2026. PBS
- Health Canada Drug Product Database (Januvia 50 mg DIN 02388847 and generic sitagliptin 50 mg, prescription) and NHS Dictionary of Medicines and Devices (generic sitagliptin 50 mg tablets, POM); searched 10 November 2026.
- Indian pharmacy listings for Januvia 50 mg (Truemeds, PharmEasy, Medkart), checked 10 November 2026, and the product photograph of the carton and strip.
- MHRA. 20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys, 13 February 2026. GOV.UK
- US Food and Drug Administration. Personal Importation. FDA
This page is for information and is not medical advice. Januvia 50mg is a prescription medicine whose dose depends on kidney function. Take it only as prescribed by a doctor who checks your kidney function and blood sugar, and stop it and get medical help at the first sign of severe stomach pain or an allergic reaction.
Frequently asked questions
What is Januvia 50mg?
Januvia 50mg is MSD's sitagliptin tablet for adults with type 2 diabetes, used with diet and exercise to lower blood sugar. Each film-coated tablet contains sitagliptin phosphate equivalent to 50 mg of sitagliptin, a DPP-4 inhibitor. We sell the Indian pack from MSD Pharmaceuticals Pvt Ltd, in strips of 7 tablets. It is not for type 1 diabetes.
Who is Januvia 50 mg for?
The US and UK Januvia labels give 50 mg once daily to adults whose kidney function is moderately reduced, with an eGFR of 30 to below 45. Most adults with an eGFR of 45 or above take 100 mg once daily, and people below 30 or on dialysis take 25 mg once daily. Your doctor sets the dose from a kidney blood test.
Why is the dose lower when kidney function is reduced?
Sitagliptin leaves the body mainly through the kidneys. At an eGFR of 30 to below 45, blood levels of sitagliptin were about twice as high as in people with normal kidneys, and about four times as high below 30 (US label 12.3; UK SmPC 5.2). The lower doses aim to give blood levels similar to those of people with normal kidney function.
How much does Januvia 50mg cost per tablet?
As of November 2026, 28 tablets cost $65 ($2.32 a tablet), 56 cost $110 ($1.96) and 84 cost $158 ($1.88); the pack selector shows the current price. Shipping is $25 under $149 and free from $149, so with shipping the 28 pack is $3.21 a tablet and the 56 pack $2.41, while the 84 pack ships free. One tablet is one day's dose (our arithmetic).
Is generic sitagliptin cheaper in the US?
Generic sitagliptin 50 mg from Teva, Sandoz and Apotex has been sold in the US since 2026. US pharmacies paid about $3.72 a tablet for it and about $10.55 for Januvia 50 mg (NADAC, effective 21 October 2026); those are acquisition costs, not counter prices. Some US pharmacies now sell generic sitagliptin 50 mg for less than our price: Cost Plus Drugs listed 30 tablets at $35.89 plus a $5 fee and shipping, about $1.54 a tablet, on 10 November 2026 (our arithmetic). An insurance copay can be lower still, so check the cash price and your copay before you compare.
Is Indian Januvia the same as US Januvia?
Both contain sitagliptin phosphate equivalent to 50 mg of sitagliptin under the MSD Januvia brand. The Indian pack comes in strips of 7 and is not registered with the FDA, MHRA, TGA or Health Canada. We have seen no bioequivalence study comparing the Indian pack with US Januvia, and the Indian tablet may look different from the US light beige tablet marked 112. Read the carton and strip you receive.
How do I take Januvia 50mg?
Take one tablet once a day, with or without food, exactly as your doctor prescribes. If you miss a dose, take it when you remember; if you do not remember until it is time for your next dose, skip the missed dose and go back to your usual schedule. Do not take two doses at the same time. Have your kidney function checked before you start and at intervals afterwards, and keep up your blood sugar and HbA1c checks.
Can I take two 50 mg tablets instead of one 100 mg tablet?
Take only the dose your doctor prescribes. Neither label gives 50 mg for people with an eGFR of 45 or above, and never raise your dose on your own: below an eGFR of 45 the labels lower the dose because sitagliptin builds up in the blood. If your doctor prescribes 100 mg, our Januvia 100mg costs $2.14 to $2.63 a tablet before shipping, less than two 50 mg tablets ($3.76 to $4.64 a day before shipping; our arithmetic).
What are the side effects of Januvia?
The most common in the US label are stuffy or runny nose with sore throat, upper respiratory infection and headache. Alone or with metformin it rarely causes low blood sugar, but the risk rises with a sulfonylurea or insulin. Serious warnings include pancreatitis, heart failure in people at risk, kidney problems, serious allergic reactions, severe joint pain and bullous pemphigoid. Stop it and get help at once for severe stomach pain or swelling of the face, lips or throat.
Who should not take Januvia 50mg?
Never take it after a serious allergic reaction to sitagliptin. It should not be used for type 1 diabetes or diabetic ketoacidosis. It is not suitable if your eGFR is 45 or above or below 30, because the label dose there is 100 mg or 25 mg. The UK label says it should not be used in pregnancy, during breastfeeding, or in children aged 10 to 17. Tell your doctor about any past pancreatitis or heart failure.
Do I need a prescription, and how long does delivery take?
Yes. Januvia and generic sitagliptin are prescription medicines in the US, UK, Canada and Australia, and Indian listings mark it prescription required. The FDA says personal importation of unapproved medicines is illegal in most circumstances. We ship to the US, UK, Australia and Canada in plain packaging with tracking in 7 to 14 business days; shipping is $25 under $149 and free from $149.
Medical References
- 1.JANUVIA (sitagliptin) tablets, US prescribing information and Medication Guide, Merck Sharp & Dohme (DailyMed SPL version 71) — 2024
- 2.Januvia 50 mg film-coated tablets, UK Summary of Product Characteristics (MSD UK, PLGB 53095/0039, POM), revised 12 October 2023 — 2023
- 3.CMS National Average Drug Acquisition Cost (NADAC) 2026, file as of 4 November 2026 — 2026
- 4.Pharmaceutical Benefits Scheme item 9181F: sitagliptin 50 mg tablet, 28
- 5.US Food and Drug Administration: Personal Importation
- 6.MHRA: 20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys — 2026
- 7.Green JB et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (TECOS). N Engl J Med 2015 (PMID: 26052984) — 2015
- 8.Rosenstock J et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events (CARMELINA). JAMA 2019 (PMID: 30418475) — 2019
- 9.Rosenstock J et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes (CAROLINA). JAMA 2019 (PMID: 31536101) — 2019
- 10.Scirica BM et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (SAVOR-TIMI 53). N Engl J Med 2013 (PMID: 23992601) — 2013
- 11.Cost Plus Drugs price list: sitagliptin 50 mg tablets, read 10 November 2026 — 2026
Sources: U.S. National Library of Medicine (DailyMed, PubMed), openFDA
Related articles
Customer Reviews
No reviews yet. Bought Januvia 50mg? Tell other buyers how it went.







